Methods
Our Pediatric Hematology-Oncology and Stem Cell Transplantation Center has a comprehensive and large database of all patients and donors. In this center, transplantations were performed using the BM product obtained by administering G-CSF to healthy donors in order to increase the number of collected total nucleated cells (TNC) and CD34 cells for some patients. The data obtained with the products collected from the BM of healthy donors after G-CSF administration were analyzed in detail. Three different products were used as G-CSF: biosimilar filgrastim (Leucostim®) (n=29), original filgrastim (Neupogen®) (n=30), and lenograstim (Granocyte®) (n=30). These G-CSFs were compared with one another and with the control group (n=30). All donors were treated with a standard institutional protocol. Approval for the study was obtained from our local institutional review board.